| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 722.00 k | 722.00 k | 722.00 k | 722.00 k | 722.00 k | 722.00 k |
| Cash burn (monthly) | (no burn) | (no burn) | 813.33 k | 1.00 mm | 153.00 k | 137.25 k |
| Cash used (since last report) | n/a | n/a | 3.69 mm | 4.54 mm | 693.77 k | 622.35 k |
| Cash remaining | n/a | n/a | -2.97 mm | -3.82 mm | 28.23 k | 99.65 k |
| Runway (months of cash) | n/a | n/a | -3.6 | -3.8 | 0.2 | 0.7 |
| 13F holders | Current |
|---|---|
| Total holders | 2 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 16.10 mm |
| Total shares | 10.37 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| CVI Investments | 7.03 mm | $0.00 |
| PDLI PDL Biopharma | 3.33 mm | $16.10 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Jan 24 | Yan Zhang | Common Stock | Sell | Dispose S | No | No | 0.0385 | 104 | 4.00 | 0 |
| 21 Dec 23 | Kamdar Kim P. | Common Stock | Sell | Dispose S | No | No | 0.621 | 10 | 6.21 | 0 |
